Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 143

Similar articles for PubMed (Select 22713338)

1.

Pharmacodynamics of the antibacterial effect of and emergence of resistance to doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an in vitro pharmacokinetic model.

Bowker KE, Noel AR, Tomaselli SG, Elliott H, Macgowan AP.

Antimicrob Agents Chemother. 2012 Oct;56(10):5009-15. doi: 10.1128/AAC.06111-11. Epub 2012 Jun 19.

3.

In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures.

Kim A, Banevicius MA, Nicolau DP.

Antimicrob Agents Chemother. 2008 Jul;52(7):2497-502. doi: 10.1128/AAC.01252-07. Epub 2008 May 5.

4.

Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development.

Tam VH, Ledesma KR, Vo G, Kabbara S, Lim TP, Nikolaou M.

Antimicrob Agents Chemother. 2008 Nov;52(11):3987-93. doi: 10.1128/AAC.01468-07. Epub 2008 Aug 25.

5.

Comparative pharmacodynamics and antimutant potentials of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model.

Firsov AA, Gilbert D, Greer K, Portnoy YA, Zinner SH.

Antimicrob Agents Chemother. 2012 Mar;56(3):1223-8. doi: 10.1128/AAC.05964-11. Epub 2011 Dec 27.

6.

Activity of doripenem with and without levofloxacin, amikacin, and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.

Pankuch GA, Seifert H, Appelbaum PC.

Diagn Microbiol Infect Dis. 2010 Jun;67(2):191-7. doi: 10.1016/j.diagmicrobio.2010.01.004. Epub 2010 Mar 24.

PMID:
20338710
7.

Pharmacodynamics of razupenem (PZ601) studied in an in vitro pharmacokinetic model of infection.

MacGowan AP, Noel A, Tomaselli S, Elliott H, Bowker K.

Antimicrob Agents Chemother. 2011 Apr;55(4):1436-42. doi: 10.1128/AAC.00936-10. Epub 2011 Jan 24.

8.

Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.

Bergen PJ, Tsuji BT, Bulitta JB, Forrest A, Jacob J, Sidjabat HE, Paterson DL, Nation RL, Li J.

Antimicrob Agents Chemother. 2011 Dec;55(12):5685-95. doi: 10.1128/AAC.05298-11. Epub 2011 Sep 12.

9.

In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.

Housman ST, Hagihara M, Nicolau DP, Kuti JL.

J Antimicrob Chemother. 2013 Oct;68(10):2296-304. doi: 10.1093/jac/dkt197. Epub 2013 May 24.

10.

Doripenem vs meropenem against Pseudomonas and Acinetobacter.

Goyal K, Gautam V, Ray P.

Indian J Med Microbiol. 2012 Jul-Sep;30(3):350-1. doi: 10.4103/0255-0857.99502.

11.
12.

Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.

MacGowan AP, Noel AR, Tomaselli S, Elliott HC, Bowker KE.

Antimicrob Agents Chemother. 2011 Feb;55(2):867-73. doi: 10.1128/AAC.00933-10. Epub 2010 Nov 15.

13.

Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.

Villegas MV, Briceno DF, Ruiz SJ, Furtado GH, Nicolau DP.

Braz J Infect Dis. 2011 Sep-Oct;15(5):413-9.

15.

Antimicrobial susceptibility patterns of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii against carbapenems, colistin, and tigecycline.

Somily AM, Absar MM, Arshad MZ, Al Aska AI, Shakoor ZA, Fatani AJ, Siddiqui YM, Murray TS.

Saudi Med J. 2012 Jul;33(7):750-5.

PMID:
22821309
16.
17.

In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.

Crandon JL, Bulik CC, Nicolau DP.

Antimicrob Agents Chemother. 2009 Oct;53(10):4352-6. doi: 10.1128/AAC.00282-09.

18.
19.

Concentration-resistance relationships with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model.

Zinner SH, Gilbert D, Greer K, Portnoy YA, Firsov AA.

J Antimicrob Chemother. 2013 Apr;68(4):881-7. doi: 10.1093/jac/dks463. Epub 2012 Nov 21.

20.

Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.

Samtani MN, Flamm R, Kaniga K, Nandy P.

Antimicrob Agents Chemother. 2010 Jun;54(6):2360-4. doi: 10.1128/AAC.01843-09. Epub 2010 Apr 12.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk